I've seen large bids the past few weeks...And yes, the price is slighty down. Somebody buying and somebody selling. Or the MM'ers are playing games to shake out weak hands. A MM'er with B IG pockets and buy and sell 100K shares to themselves to scare the weak. I think games are going on and taking advantage by picking up a few more shares.
Does Altr drop 6 pts Monday?!?!?
Analyst Ratings for ImmunoCellular Therapeutics (IMUC)
IMUC Rating Summary:
Buys – 5
Neutrals – 1
Sells – 0
IMUC Price Target Summary
Highest: $4.00 (Maxim Group)
Lowest: $3.00 (Roth Capital)
* Over Last 12-Mos
shorts may push WLL over 35
3 days ago Maxim also put a $3 target on IMUC.
I agree. I also found another recent $3 target on IMUC from Maxim Group. With these targets I would expect IMUC to hit $1.75 to $2.25 by this summer.
Maxim Group Reiterates a Buy Rating on ImmunoCellular Therapeutics (March 10th, 2015)
By Corrie Williams
In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE MKT: IMUC), with a price target of $3. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.53.
March 13th, 2015
ImmunoCellular Therapeutics Ltd (IMUC) Bullish Stance Reiterated at Roth Capital Following FY14 Results
Roth Capital’s healthcare analyst Joseph Pantginis weighed in today with a few insights on ImmunoCellular Therapeutics Ltd (NYSE MKT:IMUC), after the company reported full-year 2014 results, posting EPS of ($0.16) compared to Pantginis’ estimate of ($0.17) and consensus of ($0.15).
The analyst reiterated a Buy rating on the stock with a $3 price target, which represents a potential upside of 436% from where the stock is currently trading.
Pantginis noted, “We believe this year represents a turning point for IMUC with the expected Phase III study start with ICT-107 in newly diagnosed glioblastoma patients. IMUC also expects to have data from the Phase I study of ICT-121 in recurrent glioblastoma in 2016 as well as advance its in-licensed Stem-to-T-cell program to the clinic. We believe that as the company starts achieving these milestones, there will be renewed interest and focus in the ICT-140 asset for ovarian cancer which the company had put on hold until it finds either sufficient funds or a suitable partner to advance it into Phase II. We believe that visibility and renewed interest in the company should rise with initiation of the ICT-107 Phase III.”